Recent Updates
Recently added Catalysts
COR Positive Sentiment Score: 80/100

AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AmerisourceBergen COMPLETES ACQUISITION OF PHARMALEX Acquisition advances role as a partner of choice for biopharmaceutical companies

Key Takeaway: AmerisourceBergen Corporation has completed the acquisition of PharmaLex Holding GmbH, which bolsters its growth strategy and enhances its offerings in specialty services. This acquisition positions AmerisourceBergen as a leading partner for biopharmaceutical companies by expanding its capabilities in regulatory affairs, consulting, and quality compliance. The move is expected to strengthen its presence in the pharmaceutical development and commercialization landscape.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition enhances AmerisourceBergen's specialty services portfolio.
  • Expands leadership in global pharmaceutical manufacturer services.
  • Strengthens partnerships with biopharmaceutical companies.

Full Press Release Details

PRESS RELEASE
AmerisourceBergen Corporation
1 West First Avenue
Conshohocken, PA 19428
AmerisourceBergen COMPLETES ACQUISITION OF PHARMALEX
Acquisition advances role as a partner of choice for biopharmaceutical companies by enhancing global portfolio of specialty services
CONSHOHOCKEN, PA, January 3, 2023 - AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.
The acquisition of PharmaLex enhances AmerisourceBergen's growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex's regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen's role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey.
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.
Contacts: Investors:
Bennett S. Murphy
610-727-3693
bmurphy@amerisourcebergen.com
Media:
Lauren Esposito
215-460-6981
lesposito@amerisourcebergen.com

Frequently Asked Questions

What company did AmerisourceBergen acquire?

AmerisourceBergen completed the acquisition of PharmaLex Holding GmbH.

How does the acquisition benefit AmerisourceBergen?

The acquisition enhances AmerisourceBergen's leadership in specialty services.

What services does PharmaLex provide?

PharmaLex offers regulatory affairs, development consulting, and more.

What is AmerisourceBergen's global team size?

AmerisourceBergen has approximately 44,000 global team members.

Where is AmerisourceBergen headquartered?

AmerisourceBergen is headquartered in Conshohocken, PA.

Last updated: Jan 3, 2023